scPharmaceuticals (SCPH) Competitors $4.95 +0.17 (+3.56%) Closing price 04:00 PM EasternExtended Trading$4.95 0.00 (0.00%) As of 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock SCPH vs. AVDL, PAHC, PHVS, ARDX, GPCR, AMPH, VERV, SYRE, AKBA, and RCUSShould you be buying scPharmaceuticals stock or one of its competitors? The main competitors of scPharmaceuticals include Avadel Pharmaceuticals (AVDL), Phibro Animal Health (PAHC), Pharvaris (PHVS), Ardelyx (ARDX), Structure Therapeutics (GPCR), Amphastar Pharmaceuticals (AMPH), Verve Therapeutics (VERV), Spyre Therapeutics (SYRE), Akebia Therapeutics (AKBA), and Arcus Biosciences (RCUS). These companies are all part of the "pharmaceutical products" industry. scPharmaceuticals vs. Its Competitors Avadel Pharmaceuticals Phibro Animal Health Pharvaris Ardelyx Structure Therapeutics Amphastar Pharmaceuticals Verve Therapeutics Spyre Therapeutics Akebia Therapeutics Arcus Biosciences scPharmaceuticals (NASDAQ:SCPH) and Avadel Pharmaceuticals (NASDAQ:AVDL) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, risk, media sentiment, valuation, dividends, profitability, analyst recommendations and institutional ownership. Is SCPH or AVDL more profitable? Avadel Pharmaceuticals has a net margin of -1.32% compared to scPharmaceuticals' net margin of -183.55%. Avadel Pharmaceuticals' return on equity of -3.73% beat scPharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets scPharmaceuticals-183.55% -1,647.86% -71.76% Avadel Pharmaceuticals -1.32%-3.73%-1.73% Which has more volatility & risk, SCPH or AVDL? scPharmaceuticals has a beta of 0.4, meaning that its stock price is 60% less volatile than the S&P 500. Comparatively, Avadel Pharmaceuticals has a beta of 1.47, meaning that its stock price is 47% more volatile than the S&P 500. Do institutionals & insiders believe in SCPH or AVDL? 89.5% of scPharmaceuticals shares are owned by institutional investors. Comparatively, 69.2% of Avadel Pharmaceuticals shares are owned by institutional investors. 4.8% of scPharmaceuticals shares are owned by company insiders. Comparatively, 5.2% of Avadel Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Does the media prefer SCPH or AVDL? In the previous week, Avadel Pharmaceuticals had 10 more articles in the media than scPharmaceuticals. MarketBeat recorded 22 mentions for Avadel Pharmaceuticals and 12 mentions for scPharmaceuticals. Avadel Pharmaceuticals' average media sentiment score of 0.49 beat scPharmaceuticals' score of 0.08 indicating that Avadel Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment scPharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Avadel Pharmaceuticals 5 Very Positive mention(s) 4 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Which has stronger valuation and earnings, SCPH or AVDL? Avadel Pharmaceuticals has higher revenue and earnings than scPharmaceuticals. Avadel Pharmaceuticals is trading at a lower price-to-earnings ratio than scPharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioscPharmaceuticals$36.33M7.26-$85.15M-$1.81-2.73Avadel Pharmaceuticals$169.12M7.72-$48.83M-$0.03-450.00 Do analysts prefer SCPH or AVDL? scPharmaceuticals currently has a consensus price target of $14.00, indicating a potential upside of 182.83%. Avadel Pharmaceuticals has a consensus price target of $18.67, indicating a potential upside of 38.27%. Given scPharmaceuticals' higher probable upside, analysts clearly believe scPharmaceuticals is more favorable than Avadel Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score scPharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Avadel Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryAvadel Pharmaceuticals beats scPharmaceuticals on 12 of the 15 factors compared between the two stocks. Get scPharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SCPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCPH vs. The Competition Export to ExcelMetricscPharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$263.84M$3.08B$5.60B$9.82BDividend YieldN/A2.27%4.60%4.11%P/E Ratio-2.7320.5630.2825.72Price / Sales7.26191.64387.9280.32Price / CashN/A42.0537.7558.93Price / Book-12.387.598.456.01Net Income-$85.15M-$54.65M$3.25B$265.06M7 Day Performance-1.20%5.43%4.05%2.80%1 Month Performance10.49%6.75%4.32%1.68%1 Year Performance3.34%31.59%36.25%29.59% scPharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCPHscPharmaceuticals4.4681 of 5 stars$4.95+3.6%$14.00+182.8%-3.0%$263.84M$36.33M-2.7330News CoverageEarnings ReportShort Interest ↓AVDLAvadel Pharmaceuticals2.8959 of 5 stars$11.26+1.6%$18.33+62.8%-15.2%$1.07B$169.12M-41.7070Positive NewsEarnings ReportAnalyst RevisionPAHCPhibro Animal Health3.7033 of 5 stars$27.14+3.9%$24.40-10.1%+73.0%$1.06B$1.02B34.801,940Gap DownPHVSPharvaris2.0083 of 5 stars$21.24+6.2%$36.20+70.4%+17.2%$1.05BN/A-7.0630News CoveragePositive NewsEarnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionARDXArdelyx4.404 of 5 stars$4.39+1.4%$10.88+147.7%-0.9%$1.04B$333.61M-19.9590Options VolumeGPCRStructure Therapeutics2.4576 of 5 stars$16.78-4.6%$76.17+353.9%-44.2%$1.01BN/A0.00136Analyst RevisionAMPHAmphastar Pharmaceuticals3.1919 of 5 stars$21.40+0.9%$32.33+51.1%-30.0%$999.82M$731.97M7.752,028Analyst UpgradeVERVVerve Therapeutics2.9131 of 5 stars$11.13flat$14.57+30.9%N/A$992.13M$32.33M-5.27110SYRESpyre Therapeutics3.0911 of 5 stars$16.16-0.6%$53.40+230.4%-31.2%$980.08M$890K0.0073Positive NewsAKBAAkebia Therapeutics4.067 of 5 stars$3.76+1.1%$6.75+79.5%+146.3%$977.01M$160.18M-17.90430RCUSArcus Biosciences2.3682 of 5 stars$9.22+0.6%$21.29+131.0%-35.7%$969.91M$258M-2.20500Analyst Revision Related Companies and Tools Related Companies Avadel Pharmaceuticals Alternatives Phibro Animal Health Alternatives Pharvaris Alternatives Ardelyx Alternatives Structure Therapeutics Alternatives Amphastar Pharmaceuticals Alternatives Verve Therapeutics Alternatives Spyre Therapeutics Alternatives Akebia Therapeutics Alternatives Arcus Biosciences Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCPH) was last updated on 8/14/2025 by MarketBeat.com Staff From Our PartnersGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredHIDDEN IN THE BOOK OF GENESIS…“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredWhen the levee breaksThe U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was project...Porter & Company | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBut this $20 American company could control the secretThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMO...The Oxford Club | SponsoredBREAKING: The House just passed 3 pro-crypto bills!THREE pro-crypto bills just passed the House! Now, experts believe altcoin season is officially here. Crypto 101 Media | SponsoredGenerate up to $5,000/month with 10X less money?The secret to retiring without a million-dollar nest egg. I'm talking about generating enough monthly inco...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share scPharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access